- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
International sales fuel OEC results
Strong international acceptance of its Series 9600 mobile C-armhas helped OEC Medical Systems record sharply higher revenuesand profits for its second quarter (end-June). The Salt Lake Citycompany had second-quarter revenues of $26.1 million, up 34%
Strong international acceptance of its Series 9600 mobile C-armhas helped OEC Medical Systems record sharply higher revenuesand profits for its second quarter (end-June). The Salt Lake Citycompany had second-quarter revenues of $26.1 million, up 34% overthe $19.4 million in product sales in the same period last year.Net income was $2.8 million, compared to $300,000 in the secondquarter of 1994.
OEC was bedeviled by delays in shipping Series 9600 last yearthat were reflected in the company's 1994 results, but those bugshave been worked out, according to chairman, president and CEORuediger Naumann-Etienne. OEC's numbers this year were aided bystrong international demand for the product. International salesfor the first six months of 1995 have already exceeded the totalrecorded last year, he said.
New Study Assesses Long-Term Outcomes of PSMA PET Use in PCa Recurrence Cases
October 24th 2024For patients with biochemical recurrence of prostate cancer, PSMA PET imaging may facilitate a 12.8 percent lower incidence of prostate cancer mortality in contrast to the combination of CT and bone scan, according to long-term outcome estimates from a new decision-analytic modeling study.
Can Diffusion MRI Predict Patient Response to Neoadjuvant Chemotherapy for Breast Cancer?
October 23rd 2024A model emphasizing time-dependent diffusion MRI was 15 percent more effective than apparent diffusion coefficient (ADC) measurements at predicting pathologic complete response to neoadjuvant chemotherapy for women with breast cancer, according to new research.
